Injectable MPL allergy vaccine - Allergy Therapeutics

Drug Profile

Injectable MPL allergy vaccine - Allergy Therapeutics

Alternative Names: Birch pollen allergen extract; Birch pollen modified allergen tyrosine-absorbed; Grass MATA MPL; MPL 103; Pollinex Quattro; Pollinex Quattro Grass; Pollinex Quattro Ragweed; Pollinex Quattro Tree; Pollinex Quattro® Birch; PQ Birch; PQ Grass; Ragweed MATA MPL; Tree MATA MPL

Latest Information Update: 23 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergy Therapeutics
  • Class Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Grass pollen hypersensitivity
  • Phase III Allergic rhinoconjunctivitis; Ragweed pollen hypersensitivity
  • Phase II Seasonal allergic rhinitis; Tree pollen hypersensitivity

Most Recent Events

  • 15 Dec 2016 Phase-III clinical trials in Allergic rhinoconjunctivitis (Prevention) in Austria (SC) (EudraCT2016-002781-31)
  • 13 Jul 2016 Allergy Therapeutics plans a dose-ranging study for Grass pollen hypersensitivity (Prevention) in USA
  • 13 Jul 2016 Allergy Therapeutics plans a phase III trial for Tree pollen hypersensitivity (Prevention) in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top